Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Filippo Cademartiri: Inflammation vs Cholesterol as Driver of Residual ASCVD Risk
Filippo Cademartiri/LinkedIn
Mar 16, 2026, 13:32

Filippo Cademartiri: Inflammation vs Cholesterol as Driver of Residual ASCVD Risk

Filippo Cademartiri, Consultant Advanced Cardiovascular Imaging at UPMC Salvator Mundi International Hospital, shared on LinkedIn about a recent article by Faizan Mazhar et al, adding:

“Inflammation vs cholesterol: which residual risk matters most in ASCVD?

A large real-world study explored how cholesterol risk (LDL-C) and inflammatory risk (hsCRP) relate to cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease (ASCVD).

Researchers analyzed 39,638 patients with ASCVD in routine healthcare in Stockholm between 2007–2021. Patients were stratified into four groups based on LDL-C greater than or equal to 1.8 mmol/L (approximately 70 mg/dL) and hsCRP greater than or equal to 2 mg/L:

  • Low risk
  • High cholesterol risk
  • High inflammatory risk
  • Combined high cholesterol plus inflammatory risk

The primary endpoint was major adverse cardiovascular events (MACE), with additional outcomes including cardiovascular mortality, all-cause mortality, and heart failure hospitalization.

Key findings

Inflammatory risk mattered more than cholesterol alone!!!

Patients with high inflammatory risk (hsCRP greater than or equal to 2 mg/L) had significantly higher rates of:

  • MACE
  • cardiovascular mortality
  • all-cause mortality
  • heart failure hospitalization

High cholesterol alone was associated with only a modest increase in MACE and was not strongly linked to other adverse outcomes.

Another striking observation: approximately 39% of ASCVD patients were not receiving lipid-lowering therapy, highlighting persistent gaps in secondary prevention in routine care.

Why this matters

The study reinforces a growing concept in cardiometabolic medicine:

Residual inflammatory risk remains a major driver of cardiovascular events even when cholesterol is treated.

This helps explain why therapies targeting inflammation (e.g., colchicine, IL-1 pathways) are increasingly explored alongside lipid-lowering strategies.

Take-home message

ASCVD risk is not just about LDL-C.

In real-world populations, inflammation appears to be an equally important — and often overlooked — driver of recurrent cardiovascular events.

Future prevention strategies will likely need to target both cholesterol and inflammation. ”

Title: Inflammatory and cholesterol risks and rates of major cardiovascular events among patients with atherosclerotic cardiovascular disease in routine care

Authors: Faizan Mazhar, Davide Capodanno, Paul Hjemdahl, Arvid Sjölander, Sofia Gerward, Jimmi Mathisen, Oscar Plunde, Vijay Kunadian, Tomas Jernberg, Juan-Jesus Carrero

Read the Full Article on European Heart Journal Open

Filippo Cademartiri: Inflammation vs Cholesterol as Driver of Residual ASCVD Risk

Stay updated with Hemostasis Today.

(inflammation Arvid Sjölander ASCVD Atherosclerotic Cardiovascular Disease bleeding disorders Cholesterol Davide Capodanno European Heart Journal Open Faizan Mazhar Filippo Cademartiri Health Hematology Hemostasis Hemostasis News Hemostasis Today Jimmi Mathisen Juan-Jesus Carrero LDL-C Medicine Oscar Plunde Paul Hjemdahl Sofia Gerward thrombosis Tomas Jernberg Vijay Kunadian
NewsFeed